Protocol for reflex DNA testing in conjunction with Integrated test screening.

<p>Protocol for reflex DNA testing in conjunction with Integrated test screening.</p

Screening performance of reflex DNA tests with the Integrated test according to percentage of women having reflex DNA test (Integrated test risk cut-off 1 in 50).

<p>Screening performance of reflex DNA tests with the Integrated test according to percentage of women having reflex DNA test (Integrated test risk cut-off 1 in 50).</p

Illustration of the cost per woman screened according to the cost of the DNA test, expressed as a multiple of the cost of an Integrated test, and the proportion of women who have a DNA test (i.e. positive based on a the first trimester stage of the Integrated test, 75% of the cost of the Integrated test incurred in the first trimester).

<p>Illustration of the cost per woman screened according to the cost of the DNA test, expressed as a multiple of the cost of an Integrated test, and the proportion of women who have a DNA test (i.e. positive based on a the first trimester stage of the Integrated test, 75% of the cost of the Integrated test incurred in the first trimester).</p

Absolute and relative difference in blood pressure (BP) and lipid measurements in 84 participants while taking the Polypill, compared with the placebo.

*<p>Polypill minus placebo.</p>**<p>(Placebo minus Polypill)/placebo for each participant. Mean percentage differences are not precisely derivable from the absolute differences because of rounding and averaging within-person differences.</p

Characteristics of the trial participants including medications discontinued at randomisation and blood pressure and lipid measurements at the end of the placebo period.

*<p>Conversion to mg/dL: multiply by 38.67 for cholesterol and by 88.57 for triglyceride.</p

Flow chart of crossover trial.

<p>Flow chart of crossover trial.</p

Observed and expected reduction in blood pressure and LDL cholesterol on the Polypill.

<p>Observed and expected reduction in blood pressure and LDL cholesterol on the Polypill.</p

Number of deaths observed (O) and expected (E) by category of exposure, duration of exposure, years since first exposure, and cause.

<p>* All men were exposed for ≥ 6 months.</p><p>For category and duration of exposure see footnotes to <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0138884#pone.0138884.t001" target="_blank">Table 1</a>. IHD = ischaemic heart disease.</p><p>Number of deaths observed (O) and expected (E) by category of exposure, duration of exposure, years since first exposure, and cause.</p

Number of men exposed and man-years at risk by category of exposure, duration of exposure, and years since first exposure.

<p>* All men were exposed for ≥ 6 months.</p><p>† Men who at first had low or moderate exposures and who were subsequently highly exposed contributed man-years at risk in the low or moderate categories initially and to the high category after their first exposure in that category. The numbers of men in each category, therefore, add up to more than 427 in all, as some men contributed to more than one category. Similarly, all men who contributed man-years at risk ≥ 10 y after first exposure and for durations of exposure of ≥ 2 y also contributed to man-years at risk <10 y after first exposure and to < 2 y duration of exposure.</p><p>‡ High = men who may have been exposed to about 1–10 ppm hydrazine vapour in the ambient air; moderate = men unlikely to have been exposed to ≥ 1 ppm and probably < 0.5 ppm hydrazine vapour in the ambient air; low = men unlikely to have been exposed to hydrazine vapour.</p><p>Number of men exposed and man-years at risk by category of exposure, duration of exposure, and years since first exposure.</p

Trial Flow Diagram.

<p>Trial Flow Diagram.</p